Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

EF Hutton Reiterates Buy on Amprius Technologies, Maintains $14 Price Target

EF Hutton analyst Chip Moore reiterates Amprius Technologies (NYSE:AMPX) with a Buy and maintains $14 price target.
byBenzinga Newsdesk
March 7, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

EF Hutton analyst Chip Moore reiterates Amprius Technologies (NYSE:AMPX) with a Buy and maintains $14 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Blend Labs Announces Strategic Partnership With Haveli Investments, Including $150M Investment In The Form Of Convertible Preferred Stock With A 0% Coupon; Will Use ~$145M Of The Proceeds To Repay All Amounts Payable Under Its Existing Credit Agreement…

By Benzinga Newsdesk
April 29, 4:29 PM
Brian Sheth, Haveli's Chief Investment Officer, to Join Blend's BoardBlend Labs, Inc. (NYSE:BLND), ("Blend" or the "Company"), a leading provider of cloud banking services,and Haveli Investments ("Haveli"), a

BLND

Read More

Why Processa Pharmaceuticals Stock Is Soaring

By Erica Kollmann
January 25, 12:32 PM
Processa Pharmaceuticals shares are soaring Thursday after the company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine. Processa said the data obtained from the Phase 1b trial has been used to select two dosage regimens for the Phase 2 trial which will be in advanced or metastatic breast cancer given the FDA's agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.

PCSA